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Management of hyperglycemia in hospitalized patients has a significant bearing on outcome, in terms of both morbidity and
mortality. However, there are few national assessments of diabetes care during hospitalization which could serve as a baseline for
change. This analysis of a large clinical database (74 million unique encounters corresponding to 17 million unique patients) was
undertaken to provide such an assessment and to find future directions which might lead to improvements in patient safety. Almost
70,000 inpatient diabetes encounters were identified with sufficient detail for analysis. Multivariable logistic regression was used to
fit the relationship between the measurement of HbA1c and early readmission while controlling for covariates such as demographics,
severity and type of the disease, and type of admission. Results show that the measurement of HbA1c was performed infrequently
(18.4%) in the inpatient setting. The statistical model suggests that the relationship between the probability of readmission and the
HbA1c measurement depends on the primary diagnosis. The data suggest further that the greater attention to diabetes reflected in
HbA1c determination may improve patient outcomes and lower cost of inpatient care.

1. Introduction
It is increasingly recognized that the management of hyperglycemia in the hospitalized patient has a significant bearing
on outcome, in terms of both morbidity and mortality [1, 2].
This recognition has led to the development of formalized
protocols in the intensive care unit (ICU) setting with rigorous glucose targets in many institutions [3]. However, the
same cannot be said for most non-ICU inpatient admissions.
Rather, anecdotal evidence suggests that inpatient management is arbitrary and often leads to either no treatment at
all or wide fluctuations in glucose when traditional management strategies are employed. Although data are few,

recent controlled trials have demonstrated that protocoldriven inpatient strategies can be both effective and safe [4, 5].
As such, implementation of protocols in the hospital setting
is now recommended [6, 7]. However, there are few national
assessments of diabetes care in the hospitalized patient which
could serve as a baseline for change. The present analysis of a
large clinical database was undertaken to examine historical
patterns of diabetes care in patients with diabetes admitted
to a US hospital and to inform future directions which
might lead to improvements in patient safety. In particular,
we examined the use of HbA1c as a marker of attention to
diabetes care in a large number of individuals identified as
having a diagnosis of diabetes mellitus. We hypothesize that
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measurement of HbA1c is associated with a reduction in
readmission rates in individuals admitted to the hospital.
Databases of clinical data contain valuable but heterogeneous and difficult data in terms of missing values,
incomplete or inconsistent records, and high dimensionality
understood not only by number of features but also their
complexity. [8]. Additionally, analyzing external data is more
challenging than analysis of results of a carefully designed
experiment or trial, because one has no impact on how
and what type of information was collected. Nonetheless, it
is important to utilize these huge amounts of data to find
new information/knowledge that is possibly not available
anywhere.

2. Materials and Methods
2.1. Data Assembly. This study used the Health Facts database
(Cerner Corporation, Kansas City, MO), a national data
warehouse that collects comprehensive clinical records across
hospitals throughout the United States. Health Facts is a
voluntary program offered to organizations which use the
Cerner Electronic Health Record System. The database contains data systematically collected from participating institutions electronic medical records and includes encounter data
(emergency, outpatient, and inpatient), provider specialty,
demographics (age, sex, and race), diagnoses and in-hospital
procedures documented by ICD-9-CM codes, laboratory
data, pharmacy data, in-hospital mortality, and hospital
characteristics. All data were deidentified in compliance with
the Health Insurance Portability and Accountability Act of
1996 before being provided to the investigators. Continuity
of patient encounters within the same health system (EHR
system) is preserved.
The Health Facts data we used was an extract representing
10 years (1999–2008) of clinical care at 130 hospitals and
integrated delivery networks throughout the United States:
Midwest (18 hospitals), Northeast (58), South (28), and West
(16). Most of the hospitals (78) have bed size between 100 and
499, 38 hospitals have bed size less than 100, and bed size of
14 hospitals is greater than 500.
The database consists of 41 tables in a fact-dimension
schema and a total of 117 features. The database includes
74,036,643 unique encounters (visits) that correspond to
17,880,231 unique patients and 2,889,571 providers. Because
this data represents integrated delivery network health systems in addition to stand-alone hospitals, the data contains
both inpatient and outpatient data, including emergency
department, for the same group of patients. However, data
from out-of-network providers is not captured.
The dataset was created in two steps. First, encounters of
interest were extracted from the database with 55 attributes.
This dataset is available as a Supplementary Material available
online at http://dx.doi.org/10.1155/2014/781670 and is also in
the process of submission to the UCI Machine Learning
Repository [9] so that it is easily available to other researchers.
Second, preliminary analysis and preprocessing of the
data were performed resulting in retaining only these features
(attributes) and encounters that could be used in further
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analysis, that is, contain sufficient information. Both steps are
described in the following subsections.
2.2. Extraction of the Initial Dataset from the Database.
Information was extracted from the database for encounters
that satisfied the following criteria.
(1) It is an inpatient encounter (a hospital admission).
(2) It is a “diabetic” encounter, that is, one during which
any kind of diabetes was entered to the system as a
diagnosis.
(3) The length of stay was at least 1 day and at most 14
days.
(4) Laboratory tests were performed during the encounter.
(5) Medications were administered during the encounter.
Criteria 3-4 were applied to remove admissions for
procedures and so forth, which were of less than 23 hours
of duration and in which changes in diabetes management
were less likely to have occurred. It should be noted that the
diabetic encounters are not all encounters of diabetic patients
but rather only these encounters where diabetes was coded as
an existing health condition.
101,766 encounters were identified to fulfill all of the
above five inclusion criteria and were used in further analysis.
Attribute/feature selection was performed by our clinical
experts and only attributes that were potentially associated
with the diabetic condition or management were retained.
From the information available in the database, we extracted
55 features describing the diabetic encounters, including
demographics, diagnoses, diabetic medications, number of
visits in the year preceding the encounter, and payer information. The full list of the features and their description is
provided in Table 1.
Since we are primarily interested in factors that lead to
early readmission, we defined the readmission attribute (outcome) as having two values: “readmitted,” if the patient was
readmitted within 30 days of discharge or “otherwise,” which
covers both readmission after 30 days and no readmission at
all. The values of the readmission attribute were determined
by examination of all patient records in the database to determine the first inpatient visit after discharge. Note that 30 days
was chosen based on criteria often used by funding agencies.
Hemoglobin A1c (HbA1c) is an important measure of glucose
control, which is widely applied to measure performance of
diabetes care [10, 11]. The measurement of HbA1c at the time
of hospital admission offers a unique opportunity to assess
the efficacy of current therapy and to make changes in that
therapy if indicated (e.g., HbA1c > 8.0% on current regimen).
We considered the possibility that if an HbA1c test result
was available from a measurement (outpatient or inpatient)
done within three months prior to the sentinel admission, the
test might not be repeated. In these cases (0.1% of the total),
we used the measurement available from the previous visit.
In all other cases, measurement of HbA1c was performed
at the time of hospital admission. We examined both the
frequency of HbA1c test ordering and the response to its
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Table 1: List of features and their descriptions in the initial dataset (the dataset is also available at the website of Data Mining and Biomedical
Informatics Lab at VCU (http://www.cioslab.vcu.edu/)).
Feature name
Encounter ID
Patient number
Race
Gender
Age
Weight

Type
Numeric
Numeric
Nominal
Nominal
Nominal
Numeric

Admission type

Nominal

Discharge disposition

Nominal

Admission source

Nominal

Time in hospital

Numeric

Payer code

Nominal

Medical specialty

Nominal

Number of lab
procedures
Number of
procedures
Number of
medications
Number of outpatient
visits
Number of
emergency visits
Number of inpatient
visits
Diagnosis 1
Diagnosis 2

% missing
0%
0%
2%
0%
0%
97%
0%
0%
0%
0%
52%
53%

Numeric

Number of lab tests performed during the encounter

0%

Numeric

Number of procedures (other than lab tests) performed during the encounter

0%

Numeric

Number of distinct generic names administered during the encounter

0%

Numeric

Number of outpatient visits of the patient in the year preceding the encounter

0%

Numeric

Number of emergency visits of the patient in the year preceding the encounter

0%

Numeric

Number of inpatient visits of the patient in the year preceding the encounter

0%

Nominal
Nominal

The primary diagnosis (coded as first three digits of ICD9); 848 distinct values
Secondary diagnosis (coded as first three digits of ICD9); 923 distinct values
Additional secondary diagnosis (coded as first three digits of ICD9); 954 distinct
values
Number of diagnoses entered to the system
Indicates the range of the result or if the test was not taken. Values: “>200,” “>300,”
“normal,” and “none” if not measured
Indicates the range of the result or if the test was not taken. Values: “>8” if the result
was greater than 8%, “>7” if the result was greater than 7% but less than 8%, “normal”
if the result was less than 7%, and “none” if not measured.
Indicates if there was a change in diabetic medications (either dosage or generic
name). Values: “change” and “no change”
Indicates if there was any diabetic medication prescribed. Values: “yes” and “no”
For the generic names: metformin, repaglinide, nateglinide, chlorpropamide,
glimepiride, acetohexamide, glipizide, glyburide, tolbutamide, pioglitazone,
rosiglitazone, acarbose, miglitol, troglitazone, tolazamide, examide, sitagliptin, insulin,
glyburide-metformin, glipizide-metformin, glimepiride-pioglitazone,
metformin-rosiglitazone, and metformin-pioglitazone, the feature indicates whether
the drug was prescribed or there was a change in the dosage. Values: “up” if the dosage
was increased during the encounter, “down” if the dosage was decreased, “steady” if the
dosage did not change, and “no” if the drug was not prescribed
Days to inpatient readmission. Values: “<30” if the patient was readmitted in less than
30 days, “>30” if the patient was readmitted in more than 30 days, and “No” for no
record of readmission.

0%
0%

Diagnosis 3

Nominal

Number of diagnoses
Glucose serum test
result

Numeric

A1c test result

Nominal

Change of
medications
Diabetes medications

Description and values
Unique identifier of an encounter
Unique identifier of a patient
Values: Caucasian, Asian, African American, Hispanic, and other
Values: male, female, and unknown/invalid
Grouped in 10-year intervals: [0, 10), [10, 20), . . ., [90, 100)
Weight in pounds.
Integer identifier corresponding to 9 distinct values, for example, emergency, urgent,
elective, newborn, and not available
Integer identifier corresponding to 29 distinct values, for example, discharged to
home, expired, and not available
Integer identifier corresponding to 21 distinct values, for example, physician referral,
emergency room, and transfer from a hospital
Integer number of days between admission and discharge
Integer identifier corresponding to 23 distinct values, for example, Blue Cross\Blue
Shield, Medicare, and self-pay
Integer identifier of a specialty of the admitting physician, corresponding to 84 distinct
values, for example, cardiology, internal medicine, family\general practice, and
surgeon

Nominal

Nominal
Nominal

24 features for
medications

Nominal

Readmitted

Nominal

1%
0%
0%
0%
0%
0%

0%

0%
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result, which we defined as a change in diabetic medications.
By a “change of medication” we understand any dosage
change (increase or reduction) as well as change to a drug
with a different generic name, for example, a change of the
type of insulin or an introduction of a new drug. The database
contains detailed information about dosage but is restricted
only to medications administered during the encounter. It
was not possible to track any preadmission and discharge
medications.
We considered four groups of encounters: (1) no HbA1c
test performed, (2) HbA1c performed and in normal range,
(3) HbA1c performed and the result is greater than 8%
with no change in diabetic medications, and (4) HbA1c
performed, result is greater than 8%, and diabetic medication
was changed.
2.3. Preliminary Analysis and the Final Dataset. The original
database contains incomplete, redundant, and noisy information as expected in any real-world data. There were several
features that could not be treated directly since they had
a high percentage of missing values. These features were
weight (97% values missing), payer code (40%), and medical
specialty (47%). Weight attribute was considered to be too
sparse and it was not included in further analysis. Payer
code was removed since it had a high percentage of missing
values and it was not considered relevant to the outcome.
Medical specialty attribute was maintained, adding the value
“missing” in order to account for missing values. Large
percentage of missing values of the weight attribute can be
explained by the fact that prior to the HITECH legislation
of the American Reinvestment and Recovery Act in 2009
hospitals and clinics were not required to capture it in a
structured format.
The preliminary dataset contained multiple inpatient
visits for some patients and the observations could not
be considered as statistically independent, an assumption
of the logistic regression model. We thus used only one
encounter per patient; in particular, we considered only the
first encounter for each patient as the primary admission and
determined whether or not they were readmitted within 30
days. Additionally, we removed all encounters that resulted
in either discharge to a hospice or patient death, to avoid
biasing our analysis. After performing the above-described
operations, we were left with 69,984 encounters that constituted the final dataset for analysis.
The variables chosen to control for patient demographic
and illness severity were gender, age, race, admission source,
discharge disposition, primary diagnosis (see Table 2), medical specialty of the admitting physician, and time spent in
hospital. Values of these variables and their distribution in the
dataset are shown in Table 3.
To summarize, our dataset consists of hospital admissions
of length between one and 14 days that did not result in
a patient death or discharge to a hospice. Each encounter
corresponds to a unique patient diagnosed with diabetes,
although the primary diagnosis may be different. During
each of the analyzed encounters, lab tests were ordered and
medication was administered.
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2.4. Statistical Methods. The unit of our analysis is an
encounter; however, in order to keep the observations independent, we only analyzed one encounter per patient. After
preliminary analysis and taking into account the amount of
data, the significance level was determined by a 𝑃 value of
less than 0.01.
Multivariable logistic regression was used to fit the
relationship between the measurement of HbA1c and early
readmission while controlling for covariates such as demographics, severity and type of the disease, and type of
admission.
To assess whether the candidate covariates were significantly associated with readmission, we created the model in
four steps. Each step was followed by tests for significance
of variables with higher degree of freedom, an analysis of
deviance table, and sensitivity analysis which was done by
removing one variable at the time and looking at changes of
beta-coefficients.
First, we fitted a logistic model with all variables but
HbA1c. We refer to this model as the core model. Second, we
added HbA1c to the core model. Third, we added pairwise
interactions to the core model (without HbA1c) and kept only
the significant ones. Finally, we added pairwise interactions
with HbA1c, leaving only the significant ones in the final
model.
Graphics were used to help in the interpretation of interaction terms in the final model. The analysis was performed
in R statistical software.
2.5. Ethical and Legal Issues. This research is based on a preexisting HIPAA compliant dataset that contains no personally
identifiable information. Due to the deidentified nature of
the datasets obtained, this study was not considered human
subjects research nor required consent per the Helsinki Declaration and was therefore exempt from VCU Institutional
Review Board review.

3. Results and Discussion
As shown in Table 3, measurement of HbA1c was infrequent,
occurring in only 18.4% of encounters where diabetes mellitus
was included as an admission diagnosis. Of those in whom
the test was ordered, 51.4% were less than 8%. When an
HbA1c was not obtained, 42.5% of patients had a medication
change during the hospitalization, whereas those providers
who ordered the test appear to have been somewhat more
responsive as determined by changes in medication (55.0%,
𝑃 < 0.001). Of those in whom the test was ordered and found
to be greater than 8%, 65.0% had a documented medication
change. With respect to readmission and taken as a whole
without adjusting for covariates, measurement of HbA1c was
associated with a significantly reduced rate of readmission
(9.4 versus 8.7%, 𝑃 = 0.007). This was true regardless of
the outcome of the test. We then examined the relationship
between readmission and HbA1c adjusting for covariates
such as patient demographic and illness type and severity.
Since the gender variable was not significant (𝑃 = 0.36)
in the core model (without HbA1c), it was removed from
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Table 2: Values of the primary diagnosis in the final dataset. In the analysis, groups that covered less than 3.5% of encounters were grouped
into “other” category.
Group name

icd9 codes

Number of
encounters

% of
encounter

Circulatory

390–459, 785

21,411

30.6%

Diseases of the circulatory system

Respiratory

460–519, 786

9,490

13.6%

Diseases of the respiratory system

Digestive

520–579, 787

6,485

9.3%

Diseases of the digestive system

Diabetes

250.xx

5,747

8.2%

Diabetes mellitus

Injury

800–999

4,697

6.7%

Injury and poisoning

Musculoskeletal

710–739

4,076

5.8%

Diseases of the musculoskeletal system and connective tissue

580–629, 788

3,435

4.9%

Diseases of the genitourinary system

140–239

2,536

3.6%

Neoplasms

780, 781, 784, 790–799

2,136

3.1%

240–279, without 250

1,851

2.6%

Other symptoms, signs, and ill-defined conditions
Endocrine, nutritional, and metabolic diseases and immunity
disorders, without diabetes

680–709, 782

1,846

2.6%

Diseases of the skin and subcutaneous tissue

001–139

1,683

2.4%

Infectious and parasitic diseases

290–319

1,544

2.2%

Mental disorders

E–V

918

1.3%

External causes of injury and supplemental classification

Genitourinary
Neoplasms

Other
(17.3%)

Description

280–289

652

0.9%

Diseases of the blood and blood-forming organs

320–359

634

0.9%

Diseases of the nervous system

630–679

586

0.8%

Complications of pregnancy, childbirth, and the puerperium

360–389

216

0.3%

Diseases of the sense organs

740–759

41

0.1%

Congenital anomalies

further analysis. When tested for sensitivity, the values of
beta-coefficients in the model changed by less than 35%, with
an exception of the time in the hospital, medical specialty,
age, and primary diagnosis that changed by 77%, 47%,
49%, and 65%, respectively, when the discharge disposition
was removed. This suggests a relationship between these
variables.
The significant pairwise interactions between the covariates were discharge disposition with race (𝑃 < 0.001),
medical specialty of the admitting physician (𝑃 = 0.001),
primary diagnosis (𝑃 = 0.005), and time in hospital (𝑃 <
0.001); the specialty of the admitting physician with time in
hospital (𝑃 = 0.001) and age (𝑃 < 0.001); and the primary
diagnosis with time in the hospital (𝑃 < 0.001) and HbA1c
(𝑃 = 0.004). Only these interactions were included in the final
model.
The final model (Tables 4 and 5) suggests that the
relationship between the probability of readmission and the
HbA1c measurement significantly depends on the primary
diagnosis (note that diabetes is always one of the secondary
diagnoses). Specifically, the profile of readmission of patients
with a primary diagnosis of diabetes mellitus, after adjusting
for covariates, differs significantly from those with a primary
diagnosis of circulatory diseases (𝑃 < 0.001) and approaches
significance for those with a primary diagnosis of respiratory
diseases (𝑃 = 0.02). Figure 1 shows predicted (adjusted for
covariates) readmission rates for these three conditions which

accounted for 52.4% of all encounters. The predictions were
calculated with the mean value of the time in hospital and at
reference levels of other covariates. There was no significant
interaction with other primary diagnoses (see Figure 3).
The present study provides a striking cross-sectional view
of inpatient diabetes care for more than 70,000 admissions
in 54 hospitals in the USA. We have designed our analysis
using highly conservative criteria. Out of a total of 5 million
inpatient admissions in the database, only about 500,000
encounters (just under 10%) were clearly documented as
occurring in individuals with diabetes and only almost 70,000
satisfied our inclusion criteria. This is certainly an underestimate given the widespread lack of designation of diabetes
mellitus in hospital discharges [12] as well as the prevalence
in the USA [13]. Nevertheless, the database permitted us to
examine clinical practice over a 10-year period of over 5,000
providers.
First and foremost, the data indicate that, despite
widespread recognition of the utility of HbA1c as a performance measure of diabetes care [14, 15], the test is ordered
infrequently (18.4%) in the inpatient setting even when test
results within the previous 3 months are included (0.1%
of the total). It is possible that HbA1c values not in our
dataset were available to the practitioners and influenced
treatment patterns. However, unlikely, this could be the result
of a dual charting system where diagnosis was stored in the
electronic health record but these specific laboratory results
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Table 3: Distribution of variable values and readmissions (population size is 69,984).

Variable

Readmitted
Number of
% in group
encounters

Number of
encounters

% of the
population

57,080
4,071
2,196
6,637

81.6%
5.8%
3.1%
9.5%

5,342
361
166
590

9.4%
8.9%
7.6%
8.9%

37,234
32,750

53.2%
46.8%

3,462
2,997

9.3%
9.2%

44,339
25,645

63.4%
36.6%

3,184
3,275

7.2%
12.8%

37,277
22,800
9,907

53.3%
32.6%
14.2%

3,563
2,032
846

9.6%
8.9%
8.5%

10,642
4,213
3,541
4,984
33,641
12,963

15.2%
6.0%
5.1%
7.1%
48.1%
18.5%

1,044
309
284
492
3,237
1,093

9.8%
7.3%
8.0%
9.9%
9.6%
8.4%

21,411
5,747
9,490
6,485
4,697
4,076
3,435
2,536
12,107

30.6%
8.2%
13.6%
9.3%
6.7%
5.8%
4.9%
3.6%
17.3%

2,129
529
710
532
524
354
313
239
1,129

9.9%
9.2%
7.5%
8.2%
11.2%
8.7%
9.1%
9.4%
9.3%

HbA1c
No test was performed
Result was high and the diabetic medication was changed
Result was high but the diabetic medication was not changed
Normal result of the test
Gender
Female
Male
Discharge disposition
Discharged to home
Otherwise
Admission source
Admitted from emergency room
Admitted because of physician/clinic referral
Otherwise
Specialty of the admitting physician
Internal Medicine
Cardiology
Surgery
Family/general practice
Missing or unknown
Other
Primary diagnosis
A disease of the circulatory system (icd9: 390–459, 785)
Diabetes (icd9: 250.xx)
A disease of the respiratory system (icd9: 460–519, 786)
Diseases of the digestive system (icd9: 520–579, 787)
Injury and poisoning (icd9: 800–999)
Diseases of the musculoskeletal system and connective tissue (icd9: 710–739)
Diseases of the genitourinary system (icd9: 580–629, 788)
Neoplasms (icd9: 140–239)
Other
Race
African American
Caucasian
Other
Missing
Agea
30 years old or younger
30–60 years old
Older than 60

12,626
52,300
3,138
1,920

18.0%
74.7%
4.5%
2.7%

1,116
4,943
256
144

8.8%
9.5%
8.2%
7.5%

1,808
21,871
46,305

2.6%
31.3%
66.2%

112
1,614
4,733

6.2%
7.4%
10.2%

Age (numeric)

mean

median

1st Qu.

3rd Qu.

Age in years
Time in hospital
Days between admission and discharge (1–14)

64.9

67

55

77

4.3

3

2

6

a

After the preliminary analysis of the relationship between age and the logistic transformation of the readmission rate. See Figure 2.

Probability of readmission
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0.11
0.10
0.09
0.08
0.07
0.06
0.05
0.04
0.03
0.02
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Table 4: Coefficients of noninteraction terms estimated from the
final logistic regression model.

None

Normal

High, med.
changed

High, med.
not changed

HbA1c

Diabetes
Respiratory
Circulatory

−1.0

−1.2
−1.4

[80–90)

[70–80)

[90–100)

Age (years)

[60–70)

[50–60)

[40–50)

[30–40)

[20–30)

[10–20)

−1.6
[0–10)

Logit of probability
of readmission

Figure 1: Adjusted for covariates readmission rates by the primary
diagnosis and HbA1c measurement. Blue denotes diabetes (icd9:
250.xx), green denotes diseases of the respiratory system (icd9: 460–
519, 786), and red denotes diseases of the circulatory system (icd9:
390–459, 785). Readmission rates were predicted on the reference
values of other predictors and the mean value of time in hospital
(Table 3). The error bars represent the 95% confidence intervals for
the predicted values. Three-degree-of-freedom tests show that the
profile of readmission in the group with the primary diagnosis of
diabetes is different than the primary diagnoses being circulatory
(significant, 𝑃 < 0.001) or respiratory (borderline significant, 𝑃 =
0.02) conditions.

Figure 2: The relationship of age (grouped into intervals of 10 years)
and the logistic function of the readmission rate. One can notice
that there are three distinct intervals ([0, 30), [30, 60), and [60,
100)) where the relationship has noticeably distinct behavior. This
preliminary plot was the motivation to divide the age variable into
three categories (Table 3).

were not. We recognize this as a potential limitation to our
interpretation of the data. But similar analyses by others have
confirmed a low rate of HbA1c determinations [16]. We were
also surprised at the apparent reluctance of providers to make
changes in antihyperglycemic medications during hospitalizations. It should be pointed out that the data considered
span a 10-year period (1999–2008). Recommended standards
of care which encourage discontinuation of medications on
admission and might prompt changes in medications based
on glucose control were only recently adopted [17]. When an
HbA1c was not obtained, less than half of patients (42.5%)

Intercept∗
Home
Discharge
Other
African American
Caucasian
Race
Missing
Other∗
Emergency
Admission
Other∗
referral
Cardiology
General practice
Internal medicine
Medical specialty
Missing∗
Other
Surgery
Time in hospital∗
[30, 60)
Age
[60, 100)
<30
Diabetes
Circulatory
Digestive
Genitourinary
Diagnosis
Injury
Musculoskeletal∗
Neoplasms
Other
Respiratory
Not measured
High, changed∗
HbA1c
High, not changed∗
Normal

Estimate
−3.180
Reference
0.302
Reference
0.015
−0.335
−0.267
Reference
−0.155
−0.020
Reference
0.388
0.377
0.463
0.306
0.443
0.130
reference
0.286
1.833
reference
0.143
−0.066
−0.288
0.022
−0.627
0.146
0.065
−0.299
reference
−0.398
−0.579
0.003

𝑃 value
<2e − 16
0.119
0.760
0.012
0.009
<0.001
0.517
0.035
0.022
0.002
0.059
0.032
0.000
0.041
0.031
0.171
0.604
0.056
0.878
0.000
0.375
0.558
0.013
0.004
0.009
0.982

“Diagnosis” stands for a primary diagnosis with possible values: “circulatory”
for icd9: 390–459, 785, “digestive” for icd9: 520–579, 787, “genitourinary”
for icd9: 580–629, 788, “diabetes” for icd9: 250.xx, “injury” for icd9: 800–
999, “musculoskeletal” for icd9: 710–739, “neoplasms” for icd9: 140–239,
“respiratory” for icd9: 460–519, 786, and “other” for otherwise.
“HbA1c” variable has four values: “not measured” when the test was not
measured, “normal” if the test was measured and the result was normal,
“high, changed” when the result of HbA1c test was high and diabetic
mediations were changed, and “high, not changed” when the result of HbA1c
test was high but diabetic mediations were not changed.
∗
Coefficients significant at the 0.01 significance level.

had a medication change during the hospitalization, whereas
those providers who ordered the test appear to have been
somewhat more responsive to the data as determined by
changes in medication (55.0%, 𝑃 < 0.001). Unfortunately, we
are not able to determine what drove the medication changes
by providers in those patients in whom an HbA1c was not
obtained but persistently elevated glucose readings may well
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Table 5: Coefficients of the interaction terms estimated from the final logistic regression model.

Attribute name

Value

Attribute name

[60, 100)
Age

Medical specialty

<30

Circulatory
Digestive
Genitourinary
Injury
Musculoskelet
Neoplasms
Other
Respiratory
Caucasian
Missing
Other∗

Diagnosis

Race

𝑃-value
0.732
0.910
0.446
0.423
0.306

General Practice
Internal Medicine
Missing
Other∗
Surgery

General Practice
Internal Medicine
Missing∗
Other
Surgery∗
General Practice
Internal Medicine
Missing
Other
Surgery

−2.465
−1.980
−1.490
−2.419
−2.715
−0.073
−0.004
−0.188
0.253
0.325
−0.137
0.182
0.079
0.030
0.320
0.514
−0.030
0.340
0.211
0.237
0.391
0.733
−0.0591
−0.0357
−0.0575
−0.0517
−0.1179
0.061
−0.018
−0.112
−0.127
−0.202

0.013
0.028
0.083
0.006
0.041
0.510
0.980
0.235
0.086
0.057
0.435
0.124
0.540
0.678
0.087
<0.001
0.001
0.057
0.199
0.121
0.018
0.000
0.023
0.121
0.007
0.027
0.000
0.732
0.910
0.446
0.423
0.306

General Practice
Internal Medicine
Missing
Other∗
Surgery
Circulatory
Digestive
Genitourinary
Injury
Musculoskelet
Neoplasms
Other∗
Respiratory

−2.465
−1.980
−1.490
−2.419
−2.715
−0.036
−0.032
0.043
−0.043
0.020
−0.047
−0.060
−0.009

0.013
0.028
0.083
0.006
0.041
0.032
0.144
0.084
0.056
0.457
0.071
<0.001
0.651

Other

Discharge

Other
Time in hospital∗

General Practice
Internal Medicine
Missing
Other
Surgery∗

Time in hospital

Discharge

Medical Specialty

[60, 100)
Age

Medical specialty

<30

Time in hospital

Estimate
0.061
−0.018
−0.112
−0.127
−0.202

Discharge

Discharge

Medical Specialty

Value
General Practice
Internal Medicine
Missing
Other
Surgery

Diagnosis

Other
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Table 5: Continued.

Attribute name

HbA1c

Value
Circulatory∗a
Digestive
Genitourinary
Injury
Musculoskelet
Neoplasms
Other
Respiratoryb

Estimate
0.573
0.487
0.428
−0.183
0.754
0.122
0.305
0.313

𝑃-value
<0.001
0.092
0.164
0.612
0.037
0.806
0.129
0.175

High, not changed

Circulatorya
Digestive
Genitourinary
Injury
Musculoskelet
Neoplasms
Other
Respiratoryb

0.578
0.215
0.000
0.316
0.799
1.046
0.646
0.435

0.024
0.616
1.000
0.517
0.132
0.075
0.029
0.191

Normal

Circulatorya
Digestive
Genitourinary
Injury
Musculoskelet
Neoplasms
Other
Respiratoryb

−0.066
0.010
0.189
−0.595
−0.100
0.362
−0.060
−0.484

0.694
0.965
0.441
0.020
0.719
0.215
0.742
0.021

Value

Attribute name

High, changed

Diagnosis

“Diagnosis” stands for a primary diagnosis with possible values: “circulatory” for icd9: 390–459, 785, “digestive”—icd9: 520–579, 787; “genitourinary”—icd9:
580–629, 788, “diabetes”—icd9: 250.xx, “injury” icd9: 800–999, “musculoskeletal”—icd9: 710–739; “neoplasms”—icd9: 140–239,“ respiratory” icd9: 460–519,
786, and “other” otherwise.
“HbA1c” variable has four values: “Not measured”, when the test was not measured, “Normal” if the test was measured and the result was normal, “High,
changed” when the result of HbA1c test was high and diabetic mediations were changed, and “High, not changed” when the result of HbA1c test was high but
diabetic mediations were not changed.
a
Denotes 𝑃 value less than 0.001 for a three degree of freedom test.
b
Denotes 𝑃 value equal to 0.02 for a three degree of freedom test.
∗
Denotes coefficients significant at the 0.01 significance level.

explain the practice. It is of interest that a recent analysis
of 1274 patients with diabetes admitted for acute myocardial
infarction demonstrated only a 31% rate of glucose therapy
intensification when a clinical HbA1c result was available
[18]. With respect to readmission rate, our data suggest that,
regardless of the result, simply measuring HbA1c is associated
with a lower rate of readmission in individuals with a
primary diagnosis of diabetes mellitus, whereas those with
the frequently observed primary diagnoses of circulatory
or respiratory diseases are not. It may not be surprising
that the attention given to diabetes care in individuals with
admitting diagnoses of circulatory or respiratory diseases
may have been less than those with a primary diagnosis of
diabetes mellitus. However, our findings strongly suggest that
greater attention to diabetes care during the hospitalization
for these high-risk individuals may have a significant impact
on readmission. Our analysis cannot address cause and effect,
but the data provide strong support for development of

protocols to examine this hypothesis directly. Hospitalization
is a unique opportunity for providers to influence change
to patient’s health outcome trajectories. Resources available
in the inpatient setting are often much greater than those
available to practitioners in the outpatient setting and could
be leveraged to impact care. On average, inpatient stays
in the present dataset were 4.27 days which would permit
examination of diabetes care and development of a plan for
change should it be warranted. The importance of this is
emphasized by the readmission data provided.
We recognize that the results from the present analysis
represent a preliminary observation with limitations intrinsic
to such large health records. In addition to the limitations
of working with large clinical datasets discussed earlier, this
study is also limited by a nonrandomized study design.
Nevertheless, our data appear to support the contention
that greater attention to glucose homeostasis during hospital
admission may be warranted.
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Figure 3: Predicted (adjusted for covariates) readmission rates by the primary diagnosis and HbA1c measurement. Readmission rates were
predicted on the reference values of other predictors and the mean value of time in hospital (Table 3). The error bars represent the 95%
confidence intervals for the predicted values. The following abbreviations are used for particular icd9 codes: “circulatory” for icd9: 390–
459, 785, “digestive” for icd9: 520–579, 787, “genitourinary” for icd9: 580–629, 788, “diabetes” for icd9: 250.xx, “injury” for icd9: 800–999,
“musculoskeletal” for icd9: 710–739, “neoplasms” for icd9: 140–239, “respiratory” for icd9: 460–519, 786, and “other” for otherwise.

4. Conclusions
In conclusion, the decision to obtain a measurement of
HbA1c for patients with diabetes mellitus is a useful predictor
of readmission rates which may prove valuable in the development of strategies to reduce readmission rates and costs for
the care of individuals with diabetes mellitus. For instance,
our analysis showed that the profile of readmission differed
significantly in patients where Hba1c was checked in the setting of a primary diabetes diagnosis, when compared to those
with a primary circulatory disorder. While readmission rates
remained the highest for patients with circulatory diagnoses,
readmission rates for patients with diabetes appeared to be
associated with the decision to test for HbA1c, rather than the
values of the HbA1c result.
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